CANCER DISCOVERY 10th ANNIVERSARY SYMPOSIUM: THE NEXT DECADE OF DISCOVERIESThe first Cancer Discovery Symposium will be a celebration of the 10th anniversary of the Journal’s launch: key thought leaders will discuss the emerging areas of cancer research that will significantly move the field forward in the next 10 years. Moderated by the Editors-in-Chief of Cancer Discovery, the symposium…
Sotorasib and other selected KRASG12C inhibitors leverage differential dependence on switch-II pocket binding at amino acid position 95 to target all RASG12C isoforms, which has…
Innovent Biologics will license IBI3009, its investigational DLL3-targeted antibody–drug conjugate (ADC) for small cell lung cancer (SCLC), to Roche for $80 million upfront and payments…
Early Career Award | Cancer Discovery | American Association for Cancer Research .aacrcontent .banner{ width: 100% margin: -20px; } .aacrcontent .banner-sm{ display: none; } .right{float:…
Cancer Discovery | 14 | 11 | November 2024
Alerts | American Association for Cancer Research .main-content h1 { font-weight: 300; color: #44b13e; margin-bottom: 0; } .main-content h3 { margin-bottom: 16px; } .main-content h3…
The FDA granted accelerated approval to encorafenib (Braftovi; Array BioPharma/Pfizer), a BRAF inhibitor, in combination with the anti-EGFR mAb cetuximab (Erbitux; Eli Lilly) and the…
The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in a phase I study. The U.S. government…
Fc-enhanced anti-CTLA-4 leverages novel FcγR-dependent mechanisms to potentiate antitumor immunity and overcomes limitations of conventional anti-CTLA-4, effectively treating poorly immunogenic and refractory cancers.
The ALK tyrosine kinase inhibitor (TKI) ensartinib (Ensacove; Xcovery) was approved for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC). The…
The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in a phase I study.
